Cover Image
市場調查報告書

全球藥物濫用檢測市場未來趨勢

Global Drug Abuse Testing Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317280
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
全球藥物濫用檢測市場未來趨勢 Global Drug Abuse Testing Market 2014-2018
出版日期: 2014年10月22日 內容資訊: 英文 75 Pages
簡介

所謂藥物,是以診斷、治療、預防疾病為目的化學物質。因此,若能適當利用藥物作為醫藥品,對患者有正面效果。可是,如果藥物用在治療以外的目的,將對健康產生嚴重的問題。所謂藥物濫用檢測,是為偵測某人使用的藥物(或複數藥物的組合)的生物檢體分析方法。檢驗採用的生物檢體,有唾液和尿、血液、毛髮、呼吸、汗等。主要的檢驗手法,有免疫分析法和層析法2種。藥物濫用檢測,實施於疾病診斷和刑事案件搜查、運動員的藥檢等廣泛的用途上。全球的藥物濫用檢測市場2013∼2018年的年複合成長率(CAGR)預計達到4.71%。

本報告提供全球的藥物濫用檢測市場相關分析、疾病與檢驗方法概要和基本的市場結構、市場規模趨勢(今後5年的預測值)、各檢驗手法、各地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察

第1章 摘要整理

第2章 簡稱集

第3章 分析範圍

  • 市場概要
  • 主要的產品與服務

第4章 市場分析技術

  • 市場分析的流程
  • 分析方法

第5章 簡介

第6章 概要

  • 流行病學
  • 一般藥物濫用
  • 藥物濫用的傷害

第7章 市場環境

  • 市場概況
  • 市場規模與其預測
  • 波特的五力分析

第8章 各手法的市場分析

第9章 各地區的分析

  • 南北美洲市場
  • 歐洲、中東、非洲(EMEA)地區市場
  • 亞太地區市場

第10章 購買標準

第11章 促進市場成長的要素

第12章 推動因素與其影響力

第13章 市場課題

第14章 推動因素、課題的影響力

第15章 市場趨勢

第16章 市場趨勢與其影響

第17章 供應商環境

  • 競爭方案
    • 近幾年的主要趨勢
    • 企業合併、收購(M&A)
  • 市場佔有率分析
  • 其他的著名供應商

第18章 主要供應商分析

  • Bio-Rad
    • 主要資料
    • 產業概要
    • 產業分類
    • 產業策略
    • 各部門的市場收益額(最新價值)
    • 各部門的市場收益額(與前年度的比較)
    • 各地區的市場收益額
    • 近幾年趨勢
    • SWOT分析
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens
  • Thermo Fisher Scientific

第19章 其他相關分析

圖表一覽

目錄
Product Code: IRTNTR4393

About Drug Abuse Testing

Drugs are chemical substances, which are generally used in the diagnosis, treatment, and prevention of diseases. Drugs when used as medicines have positive effects on patients; however, some people use drugs for non-medical purposes, which leads to serious health problems. Drug abuse testing is a technical analysis of biological specimen to determine the drugs or combination of drugs consumed by a person. The biological specimens used for the test are saliva, urine, blood, hair, breath, and sweat. The two main technologies used to test drug abuse are immunoassay and chromatography. Drug abuse testing is widely used in diagnostics, criminal cases, and to screen sports athletes.

TechNavio's analysts forecast the Global Drug Abuse Testing market to grow at a CAGR of 4.71 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Drug Abuse Testing market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography.

TechNavio's report, the Global Drug Abuse Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Drug Abuse Testing market landscape and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bio-Rad Laboratories
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Abbott Laboratories
  • Agilent Technologies
  • Alere
  • Biomedical Diagnostics
  • Branan Medical
  • OraSure Technologies
  • PerkinElmer
  • Psychemedics
  • Quest Diagnostic
  • Randox Laboratories
  • Sigma-Aldrich
  • Sonic Healthcare
  • Waters

Market Driver

  • Rise in Consumption of Illicit Drugs
  • For a full, detailed list, view our report

Market Challenge

  • Inability to Detect Low-dose Designer Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increase in Number of Collaborations and M&A
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Overview

  • 06.1. Epidemiology
  • 06.2. Commonly Abused Drugs:
  • 06.3. Harm Caused by Drugs Abuse

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Technique

09. Geographical Segmentation

  • 09.1. Drugs Abuse Testing Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. Drugs Abuse Testing Market in EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. Drugs Abuse Testing Market in APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Vendor Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Bio-Rad
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Strategy
    • 18.1.5. Business Segmentation by Revenue
    • 18.1.6. Business Segmentation by Revenue 2011KKKKK and 2012
    • 18.1.7. Geographical Segmentation by Revenue 2012
    • 18.1.8. Key Developments
    • 18.1.9. SWOT Analysis
  • 18.2. Danaher
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Revenue by Business Segmentation
    • 18.2.5. Revenue Comparison 2012KKKKK and 2013
    • 18.2.6. Segmentation by Geography
    • 18.2.7. Business Strategy
    • 18.2.8. Key Information
    • 18.2.9. SWOT Analysis
  • 18.3. F. Hoffmann-La Roche
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.3.5. Geographical Segmentation by Revenue 2013
    • 18.3.6. Business Strategy
    • 18.3.7. Recent Developments
    • 18.3.8. SWOT Analysis
  • 18.4. Siemens
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation 2013
    • 18.4.4. Revenue by Business Segmentation 2013
    • 18.4.5. Revenue Comparison by Business Segmentation 2012KKKKK and 2013
    • 18.4.6. Geographical Segmentation by Revenue 2013
    • 18.4.7. Business Strategy
    • 18.4.8. Recent Developments
    • 18.4.9. SWOT Analysis
  • 18.5. Thermo Fisher Scientific
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation
    • 18.5.4. Business Segmentation by Revenue
    • 18.5.5. Product Segmentation by Revenue
    • 18.5.6. Geographical Segmentation by Revenue 2013
    • 18.5.7. Business Strategy
    • 18.5.8. Key Information
    • 18.5.9. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Harm Caused by Drugs Abuse
  • Exhibit 3: Global Drugs Abuse Testing Market 2013-2018 (US$ million)
  • Exhibit 4: Global Drugs Abuse Testing Market Segmentation by Technology
  • Exhibit 5: Global Drugs Abuse Testing Market Segmentation by Geography 2013
  • Exhibit 6: Drugs Abuse Testing Market in Americas 2013-2018 (US$ million)
  • Exhibit 7: Drugs Abuse Testing Market in EMEA Region 2013-2018 (US$ million)
  • Exhibit 8: Drugs Abuse Testing Market in APAC Region 2013-2018 (US$ million)
  • Exhibit 9: Bio-Rad: Business Segmentation
  • Exhibit 10: Bio-Rad: Business Segmentation by Revenue 2012
  • Exhibit 11: Bio-Rad: Business Segmentation by Revenue 2011 and 2012 (US$ million)
  • Exhibit 12: Bio-Rad: Geographical Segmentation by Revenue 2012
  • Exhibit 13: Danaher: Business Segmentation
  • Exhibit 14: Danaher: Business Segmentation 2013
  • Exhibit 15: Danaher: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 16: Danaher: Revenue by Geographical Segmentation 2013
  • Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals)
  • Exhibit 20: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics)
  • Exhibit 21: Siemens: Business Segmentation 2013
  • Exhibit 22: Siemens: Revenue by Business Segmentation 2013
  • Exhibit 23: Siemens: Revenue by Business Segmentation 2012 and 2013 (US$ billion)
  • Exhibit 24: Siemens: Geographical Segmentation by Revenue 2013
  • Exhibit 25: Thermo Fisher: Business Segmentation
  • Exhibit 26: Thermo Fisher: Business Segmentation by Revenue 2013
  • Exhibit 27: Thermo Fisher: Product Segmentation by Revenue 2013
  • Exhibit 28: Thermo Fisher: Geographical Segmentation by Revenue 2013
Back to Top